Fluidigm, Novartis Amend MDx Alliance | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Fluidigm disclosed in a document filed with the US Securities and Exchange Commission on Monday that it and Novartis Vaccines and Diagnostics have amended an agreement for the development of molecular diagnostics based on Fluidigm's digital PCR system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.